loader
Please Wait
Applying Filters...

Annual Sales of Deferasirox reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

Menu
$ API Ref.Price (USD/KG) : 408Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 3Exjade

02 6Exjade/Jadenu

PharmaCompass

01

Brand Name : Exjade/Jadenu

Deferasirox

arrow
FNCE 2024
Not Confirmed

Brand Name : Exjade/Jadenu

arrow
FNCE 2024
Not Confirmed

Deferasirox

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 653

2019 Revenue in Millions : 975

Growth (%) : -33

blank

02

Brand Name : Exjade/Jadenu

Deferasirox

arrow
FNCE 2024
Not Confirmed

Brand Name : Exjade/Jadenu

arrow
FNCE 2024
Not Confirmed

Deferasirox

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 563

2020 Revenue in Millions : 653

Growth (%) : -14

blank

03

Brand Name : Exjade/Jadenu

Deferasirox

arrow
FNCE 2024
Not Confirmed

Brand Name : Exjade/Jadenu

arrow
FNCE 2024
Not Confirmed

Deferasirox

Main Therapeutic Indication : Hematology

Currency : USD

2022 Revenue in Millions : 323

2021 Revenue in Millions : 563

Growth (%) : -43

blank

04

Brand Name : Exjade

Deferasirox

arrow
FNCE 2024
Not Confirmed

Brand Name : Exjade

arrow
FNCE 2024
Not Confirmed

Deferasirox

Main Therapeutic Indication : Blood Related Disorders

Currency : USD

2014 Revenue in Millions : 3.70%

2013 Revenue in Millions :

Growth (%) :

blank

05

Brand Name : Exjade

Deferasirox

arrow
FNCE 2024
Not Confirmed

06

Brand Name : Exjade

Deferasirox

arrow
FNCE 2024
Not Confirmed

07

Brand Name : Exjade/Jadenu

Deferasirox

arrow
FNCE 2024
Not Confirmed

Brand Name : Exjade/Jadenu

arrow
FNCE 2024
Not Confirmed

Deferasirox

Main Therapeutic Indication : Oncology

Currency : USD

2017 Revenue in Millions : 1,059

2016 Revenue in Millions : 956

Growth (%) : 11

blank

08

Brand Name : Exjade/Jadenu

Deferasirox

arrow
FNCE 2024
Not Confirmed

Brand Name : Exjade/Jadenu

arrow
FNCE 2024
Not Confirmed

Deferasirox

Main Therapeutic Indication : Oncology

Currency : USD

2018 Revenue in Millions : 1,099

2017 Revenue in Millions : 1,059

Growth (%) : 4%

blank

09

Brand Name : Exjade/Jadenu

Deferasirox

arrow
FNCE 2024
Not Confirmed

Brand Name : Exjade/Jadenu

arrow
FNCE 2024
Not Confirmed

Deferasirox

Main Therapeutic Indication : Oncology

Currency : USD

2019 Revenue in Millions : 975

2018 Revenue in Millions : 1,099

Growth (%) : -11

blank